RU2007106862A - Способы и композиции для модуляции фактора роста гепатоцитов - Google Patents
Способы и композиции для модуляции фактора роста гепатоцитов Download PDFInfo
- Publication number
- RU2007106862A RU2007106862A RU2007106862/13A RU2007106862A RU2007106862A RU 2007106862 A RU2007106862 A RU 2007106862A RU 2007106862/13 A RU2007106862/13 A RU 2007106862/13A RU 2007106862 A RU2007106862 A RU 2007106862A RU 2007106862 A RU2007106862 A RU 2007106862A
- Authority
- RU
- Russia
- Prior art keywords
- hgf
- pro
- substrate
- sample
- hepsin
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Claims (7)
1. Способ идентификации ингибирующего вещества-кандидата, которое ингибирует активацию HGF гепсином, где указанный способ включает в себя (a) приведение вещества-кандидата в контакт с первым образцом, содержащим гепсин и субстрат про-HGF, и (b) сравнение степени активации субстрата про-HGF в образце со степенью активации субстрата про-HGF в эталонном образце, содержащем равные с первым образцом количества гепсина и субстрата про-HGF, но не контактировавшим с указанным веществом-кандидатом, согласно которому уменьшение степени активации субстрата про-HGF в первом образце по сравнению с эталонным образцом означает, что вещество-кандидат способно ингибировать активацию одноцепочечного HGF (про-HGF) гепсином.
2. Способ по п.1, где гепсин в образце находится в эффективном для активации указанного про-HGF количестве.
3. Способ по п.1, где субстрат про-HGF представляет собой полипептид, содержащий HGF или его фрагмент, содержащий форму пептидной связи R494-V495 дикого типа.
4. Способ по п.1, где субстрат про-HGF содержит участок расщепления человеческого HGF, соответствующий консенсусному участку расщепления протеаз, где участок расщепления содержит основный остаток в положении P1 и два гидрофобных аминокислотных остатка в положениях P1' и P2'.
5. Молекула-антагонист, ингибирующая взаимодействие гепсина и фактора роста гепатоцитов.
6. Молекула-антагонист по п.5, где молекула содержит антитело или его фрагмент.
7. Молекула-антагонист по п.5, где молекула содержит полипептид, содержащий последовательность домена 1 Кунитца.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59133904P | 2004-07-26 | 2004-07-26 | |
US60/591,339 | 2004-07-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007106862A true RU2007106862A (ru) | 2008-09-10 |
RU2405041C2 RU2405041C2 (ru) | 2010-11-27 |
Family
ID=35094502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007106862/10A RU2405041C2 (ru) | 2004-07-26 | 2005-07-25 | Способы и композиции для модуляции активации фактора роста гепатоцитов |
Country Status (16)
Country | Link |
---|---|
US (3) | US7432044B2 (ru) |
EP (1) | EP1774022B1 (ru) |
JP (2) | JP5226308B2 (ru) |
KR (1) | KR101222254B1 (ru) |
CN (1) | CN101023182B (ru) |
AU (1) | AU2005269463B2 (ru) |
BR (1) | BRPI0512482A (ru) |
CA (1) | CA2570323C (ru) |
ES (1) | ES2532610T3 (ru) |
HK (1) | HK1100294A1 (ru) |
IL (1) | IL179917A0 (ru) |
MX (1) | MX2007001064A (ru) |
NZ (1) | NZ551908A (ru) |
RU (1) | RU2405041C2 (ru) |
WO (1) | WO2006014928A1 (ru) |
ZA (1) | ZA200700745B (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2539772C2 (ru) * | 2009-10-22 | 2015-01-27 | Дженентек, Инк. | Способы и композиции для модуляции гепсином стимулирующего макрофаги белка |
RU2559533C2 (ru) * | 2009-10-22 | 2015-08-10 | Дженентек, Инк. | Антитела против гепсина и способы их применения |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962639A (en) | 1987-11-06 | 1999-10-05 | Washington Research Foundation | Synthetic peptides corresponding to telopeptide sequences of cross-linked type I collagen metabolites |
WO2000062065A1 (en) * | 1999-04-09 | 2000-10-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Complex formed by n-linked glycoproteins (siblings) and factor h |
EP2275547B1 (en) | 2004-12-13 | 2014-03-05 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
RU2009101813A (ru) | 2006-06-22 | 2010-07-27 | Дженентек, Инк. (Us) | Способы и композиции для направленного воздействия на гепсин |
US20100061996A1 (en) * | 2006-06-22 | 2010-03-11 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
WO2008102452A1 (ja) * | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Hgf製剤 |
US20110206704A1 (en) * | 2009-10-19 | 2011-08-25 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activator |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
KR20120100027A (ko) * | 2011-03-02 | 2012-09-12 | 한국생명공학연구원 | 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물 |
WO2013070771A1 (en) * | 2011-11-07 | 2013-05-16 | Isis Pharmaceuticals, Inc. | Administration of factor xi antisense oligonucleotides |
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
US11547743B2 (en) | 2014-04-28 | 2023-01-10 | Eisai R&D Management Co., Ltd. | Lyophilized formulation of HGF |
US11130780B2 (en) | 2015-03-09 | 2021-09-28 | Washington University | Inhibitors of growth factor activation enzymes |
WO2017147298A1 (en) * | 2016-02-23 | 2017-08-31 | The Regents Of The University Of Colorado, A Body Corporate | Peptide-based methods for treating neurological injury |
HUE055414T2 (hu) | 2016-03-17 | 2021-11-29 | Eisai R&D Man Co Ltd | Eljárás aktivált hepatocita növekedési faktor (HGF) elõállítására |
CA3124682A1 (en) * | 2019-01-28 | 2020-08-06 | Toray Industries, Inc. | Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US6037136A (en) * | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
ATE292476T1 (de) * | 1995-08-29 | 2005-04-15 | Anges Mg Inc | Ein medikament,das hgf gen enthält |
US7282198B2 (en) | 1997-03-19 | 2007-10-16 | The University Of Arkansas For Medical Sciences | Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme |
US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
US6423543B1 (en) | 2000-12-20 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of hepsin expression |
US20030013097A1 (en) | 2001-01-23 | 2003-01-16 | Welsh John Barnard | Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
EP1373565A2 (en) | 2001-02-14 | 2004-01-02 | Tularik Inc. | Methods for the diagnosis and treatment of tumors employing the hepsin gene |
US6482630B2 (en) | 2001-03-29 | 2002-11-19 | Applera Corporation | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
AU2003225540A1 (en) | 2002-01-31 | 2003-09-02 | Irm, Llc | Hepsin substrates and prodrugs |
US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
WO2004009803A2 (en) | 2002-07-23 | 2004-01-29 | Bayer Healthcare Ag | Regulation of human hepsin |
JP2006507813A (ja) | 2002-10-04 | 2006-03-09 | シエーリング アクチエンゲゼルシャフト | 置換体活性化配列を有する修飾されたヘプシン分子及びその使用 |
-
2005
- 2005-07-25 WO PCT/US2005/026446 patent/WO2006014928A1/en active Application Filing
- 2005-07-25 ZA ZA200700745A patent/ZA200700745B/en unknown
- 2005-07-25 JP JP2007523715A patent/JP5226308B2/ja not_active Expired - Fee Related
- 2005-07-25 RU RU2007106862/10A patent/RU2405041C2/ru not_active IP Right Cessation
- 2005-07-25 NZ NZ551908A patent/NZ551908A/en not_active IP Right Cessation
- 2005-07-25 AU AU2005269463A patent/AU2005269463B2/en not_active Ceased
- 2005-07-25 ES ES05775274.3T patent/ES2532610T3/es active Active
- 2005-07-25 BR BRPI0512482-4A patent/BRPI0512482A/pt not_active IP Right Cessation
- 2005-07-25 CA CA2570323A patent/CA2570323C/en not_active Expired - Fee Related
- 2005-07-25 EP EP05775274.3A patent/EP1774022B1/en active Active
- 2005-07-25 KR KR1020077001874A patent/KR101222254B1/ko not_active IP Right Cessation
- 2005-07-25 CN CN2005800316874A patent/CN101023182B/zh not_active Expired - Fee Related
- 2005-07-25 MX MX2007001064A patent/MX2007001064A/es active IP Right Grant
- 2005-07-25 US US11/189,230 patent/US7432044B2/en not_active Expired - Fee Related
-
2006
- 2006-12-07 IL IL179917A patent/IL179917A0/en not_active IP Right Cessation
-
2007
- 2007-06-16 HK HK07106500.3A patent/HK1100294A1/xx not_active IP Right Cessation
-
2008
- 2008-08-29 US US12/201,481 patent/US20090075317A1/en not_active Abandoned
-
2010
- 2010-03-10 US US12/721,474 patent/US20100209956A1/en not_active Abandoned
-
2012
- 2012-05-21 JP JP2012115809A patent/JP2012196217A/ja not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2539772C2 (ru) * | 2009-10-22 | 2015-01-27 | Дженентек, Инк. | Способы и композиции для модуляции гепсином стимулирующего макрофаги белка |
RU2559533C2 (ru) * | 2009-10-22 | 2015-08-10 | Дженентек, Инк. | Антитела против гепсина и способы их применения |
Also Published As
Publication number | Publication date |
---|---|
ES2532610T3 (es) | 2015-03-30 |
EP1774022A1 (en) | 2007-04-18 |
HK1100294A1 (en) | 2007-09-14 |
JP2012196217A (ja) | 2012-10-18 |
JP2008507295A (ja) | 2008-03-13 |
US20100209956A1 (en) | 2010-08-19 |
KR20070037499A (ko) | 2007-04-04 |
ZA200700745B (en) | 2008-07-30 |
BRPI0512482A (pt) | 2008-03-11 |
CN101023182B (zh) | 2013-04-17 |
KR101222254B1 (ko) | 2013-01-16 |
CA2570323A1 (en) | 2006-02-09 |
EP1774022B1 (en) | 2014-12-31 |
AU2005269463B2 (en) | 2011-08-18 |
NZ551908A (en) | 2009-10-30 |
IL179917A0 (en) | 2007-05-15 |
RU2405041C2 (ru) | 2010-11-27 |
MX2007001064A (es) | 2007-04-12 |
CN101023182A (zh) | 2007-08-22 |
US20060084120A1 (en) | 2006-04-20 |
CA2570323C (en) | 2014-08-26 |
US20090075317A1 (en) | 2009-03-19 |
JP5226308B2 (ja) | 2013-07-03 |
US7432044B2 (en) | 2008-10-07 |
AU2005269463A1 (en) | 2006-02-09 |
WO2006014928A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007106862A (ru) | Способы и композиции для модуляции фактора роста гепатоцитов | |
US20170176458A1 (en) | Fibrosis Biomarker Assay | |
ATE382148T1 (de) | Antikörper für apoptosemarker und anwendungsverfahren | |
JP5606435B2 (ja) | トロンビン基質およびサンプル中の生体活性トロンビンのレベルを測定するためのアッセイ | |
ATE423127T1 (de) | Peptidinhibitoren der ns3-protease des hepatoitis c virus | |
DK2230299T3 (da) | Hidtil ukendt cytokin ZCYTOR17-ligand | |
ATE530644T1 (de) | Protease-screening-verfahren und dadurch identifizierte proteasen | |
WO2007127977A3 (en) | Methods of evaluating peptide mixtures | |
DE69723485D1 (de) | Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease | |
ATE537448T1 (de) | Nachweis von rho-proteinen | |
ATE386798T1 (de) | Verfahren zur reindarstellung des proenzyms der den blutgerinnungsfaktor vii aktivierenden protease mittels ionenaustauscherchromatographie | |
RU2009143671A (ru) | Высокочувствительные иммуноанализы и наборы для определения представляющих интерес пептидов и белков | |
DK1336109T3 (da) | Kit og fremgangsmåde til at påvise proteinet EMS-1 | |
Kim et al. | Amino acid sequence of piguamerin, an antistasin‐type protease inhibitor from the blood sucking leech Hirudo nipponia | |
DE50304608D1 (de) | Sandwich-immunoassay zur bestimmung von proanp-teilpeptiden | |
HIRAO et al. | Purification and characterization of cathepsin B from monkey skeletal muscle | |
RU2014125266A (ru) | Анализ содержания фибриногена | |
DE60211849D1 (de) | Verfahren zur Identifizierung von Liganden eines biologischen Substrats | |
NO20053990L (no) | Assay for proteinisoformer | |
Kelly et al. | An aminopeptidase from mouse brain cytosol that cleaves N‐terminal acidic amino acid residues | |
WO2008142664A3 (en) | Exposed thymidine kinase 1 peptides, ligands and methods employing the same | |
ATE335816T1 (de) | Verfahren zum nachweis prokaryontischer dna | |
EP1739425A4 (en) | TESTING TECHNIQUE TO IDENTIFY A MEDICINAL CANDIDATE | |
Ohta et al. | Interaction of antistasin-related peptides with factor Xa: identification of a core inhibitory sequence | |
RU98106859A (ru) | Новое антитело, соединение с активностью ренина, содержащее новое антитело, и реактив для определения проренина с использованием нового антитела |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170726 |